More than 150 million people are positive for the Hepatitis C Virus (HCV) and more than 350,000 people die every year as a result of HCV-related liver disease, according to the World Health Organization. Despite this, 2014 will likely prove to be a landmark year for treatment of this infectious disease. Information will be disseminated rapidly in the next few years, and the physician communities who treat patients with HCV will need to interpret and adapt to the new paradigm.
HCV Next will bridge the gap between cutting edge news and the patient with HCV, by seeking to provide physicians with peer context and perspective on the latest research developments. Topics that will be discussed regularly in HCV Next are diagnostics, drug/drug interaction, combination therapies, guidelines, practice management issues, regulatory aspects, coding, general economic issues and treatment of patients in special populations and those with comorbidities.